keyboard_arrow_up

Nano packages for anti-cancer drug delivery

Nano packages for anti-cancer drug delivery

Cancer stem cells are resistant to chemotherapy and consequently tend to remain in the body even after a course of treatment has finished, where they can often trigger cancer recurrence or metastasis. A new study by researchers from the A*STAR Institute of Bioengineering and Nanotechnology has found that using nanoparticles to deliver an anti-cancer drug that simultaneously kills cancer cells and cancer stem cells significantly reduces the recurrence and metastasis of lung cancer. Read more on Phys Org website.Phenformin-loaded nanoparticles kill both cancer cells and cancer stem cells, leading to tumor regression.

Nanotechnologies in Drug Delivery Congress to be held on 27 – 28 April 2015 at the London Heathrow Marriot Hotel in London – UK will gather global nano-medicine experts to delve into the latest developments in the field of nanotechnology in drug delivery. The registrations for the congress are closing on 17th April 2015; register your team today.

Presenting at the congress will be organizations such as

  • AstraZeneca
  • University of Liverpool
  • Lloyds Register Quality Assurance
  • World Nano Foundation
  • Nemaura Pharma
  • University of Oxford
  • King’s College London
  • University of London
  • French Society of Nanomedicine
  • University of Strathclyde
  • University of Leeds
  • Uppsala University

Event Sponsors include



Some of the key topics to be covered are:

  • European Medical Devices Regulation of Nanotechnologies in Drug Delivery
  • The role of Nanomedicine and Targeted Medicine for Personalised Medicine
  • Real-time, whole body, tracking of nanoparticle biodistribution using multispectral optoacoustic tomography
  • Tailored Cell Targeting and Intracellular Delivery of Macromolecular Therapeutics
  • Mesoporous silica nanoparticles as a drug delivery system for anticancer therapy
  • Using Nanomedicines to Address Therapeutic Index Challenges
  • Combining High Efficiency Darkfield Illumination and Hyperspectral Imaging to Map Changes in Nanoparticle Surface Chemistry

Nanotechnology Enabled Drug Delivery to Influence Future Diagnosis and Treatments of Diseases

Diagnosis and drug delivery for diseases like cancer, cardiovascular and genetic ailments has always been a concern. In recent years, however, new strides and developments in the nano-medicine market have facilitated more effective diagnosis and drug delivery for diseases. Not only can these diseases now be studied better but it will also help us in making informed decisions producing better cures. The nano-medicine market is on a steady growth and with a compound annual growth rate (CAGR) of 12.5% from 2011; the market size will reach to $130.9 billion by 2016. To view the entire press release visit Nanotechnology Now.

Nanotechnology Platform Shows Promise for Treating Pancreatic Cancer

Scientists at UCLA’s California NanoSystems Institute and Jonsson Comprehensive Cancer Center have combined their nanotechnology expertise to create a new treatment that may solve some of the problems of using chemotherapy to treat pancreatic cancer. The study, published online in the journal ACS Nano, describes successful experiments to combine two drugs within a specially designed mesoporous silica nanoparticle that looks like a glass bubble. The drugs work together to shrink human pancreas tumors in mice as successfully as the current standard treatment, but at one twelfth the dosage. Visit BioScience Technology for more information.

Fighting cancer and Ebola with nanoparticles

In medicine, finding a substance that attacks cancerous tumors without destroying the healthy tissue around it has long been the Holy Grail.
From targeted remedies such as monoclonal antibodies to surgery, cancer has still managed to elude a treatment that discretely and separately attacks it alone.
Nanotechnologies, however - the manipulation of matter at a molecular and even atomic scale to penetrate living cells -- are holding out the promise of opening a new front against deadly conditions from cancer to Ebola. According to Dr. Thomas Webster, the chair of chemical engineering at Northeastern University in Boston, research into medical nanotechnology is gaining pace and the medical establishment is starting to sit up and pay attention. For more information visit CNN.

Upcoming industry related events:

1.       Cancer Diagnosis and Therapy Congress | 3 – 4 September 2015 | London – UK

 
Speaker representation from

  • Celgene, USA
  • Agenus & 4-Antibody AG, Switzerland
  • European Society of Surgical Oncologists, UK
  • Imperial College London, UK
  • Wolfgang Goethe-University, Germany
  • University of Manchester, UK
  • The British Association for Cancer Research, UK

  • Guangzhou East Cancer Hospital, China
  • Metropolitan Hospital, Greece
  • Cancer Science Institute of Singapore, Singapore
  • University of Buenos Aires, Argentina
  • Queen Mary University of London, UK
  • Nanomerics Ltd, UK
  • APeX Disease Reserch Institute, USA


2.      
The Epigenetics Discovery Congress | 24 – 25 September 2015 | London - UK


Speaker representation from

  • GSK,UK
  • Celgene, USA
  • Cellzome, Germany
  • Oryzon, Spain
  • Epizyme, USA

  • EpiTherapeutics ApS, Denmark
  • The Babraham Institute, UK
  • Novartis, Swizerland
  • Cambridge Biomedical Centre, UK
  • University of Oxford, UK

 
Warm Regards,

Oliver Smith
Marketing Manager | MarketsandMarkets Conferences